CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Cash flows from operating activities:
Net loss	$ (547,795)	$ (340,167)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	15,586	6,611
Non-cash operating lease costs	25,895	24,840
Amortization of deferred commissions	26,824	21,233
Stock-based compensation, net of amounts capitalized	459,392	157,790
Net amortization of premiums on investments	36,938	1,117
Unrealized gains on strategic investments in equity securities	(8,515)	0
Other	2,535	4,073
Changes in operating assets and liabilities, net of effect of business combinations:
Accounts receivable	39,142	9,221
Deferred commissions	(52,892)	(27,261)
Prepaid expenses and other assets	(112,798)	(29,480)
Accounts payable	4,591	(3,806)
Accrued expenses and other liabilities	43,106	22,477
Operating lease liabilities	(24,758)	(23,418)
Deferred revenue	124,030	111,739
Net cash provided by (used in) operating activities	31,281	(65,031)
Cash flows from investing activities:
Purchases of property and equipment	(12,209)	(24,018)
Capitalized internal-use software development costs	(8,612)	(4,014)
Cash paid for business combinations, net of cash acquired	0	(6,035)
Purchases of intangible assets	(11,182)	(6,184)
Purchases of investments	(3,042,396)	(1,235,020)
Sales of investments	407,003	28,705
Maturities and redemptions of investments	2,610,429	371,528
Net cash used in investing activities	(56,967)	(875,038)
Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	0	478,573
Proceeds from initial public offering and private placements, net of underwriting discounts	0	4,242,284
Proceeds from early exercised stock options	0	159
Proceeds from exercise of stock options	90,444	31,100
Proceeds from issuance of common stock under the employee stock purchase plan	52,227	0
Proceeds from repayments of a nonrecourse promissory note	0	2,090
Repurchases of early exercised stock options	0	(30)
Payments of deferred purchase consideration for business combinations	0	(1,164)
Net cash provided by financing activities	142,671	4,753,012
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	21	0
Net increase in cash, cash equivalents, and restricted cash	117,006	3,812,943
Cash, cash equivalents, and restricted cash—beginning of period	835,193	141,976
Cash, cash equivalents, and restricted cash—end of period	952,199	3,954,919
Supplemental disclosures of non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	3,115	2,803
Stock-based compensation included in capitalized software development costs	18,923	1,020
Vesting of early exercised stock options and restricted common stock	615	3,251
Intangible assets included in accrued expenses and other liabilities	4,544	0
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	935,217	3,939,925
Restricted cash – included in other assets and prepaid expenses and other current assets	16,982	14,994
Total cash, cash equivalents, and restricted cash	$ 952,199	$ 3,954,919